˹

Human Growth Hormone Franchise

About NGENLA™

NGENLA™ (somatrogon-ghla) is approved by the U.S. Food and Drug Administration as a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Growth hormone deficiency is a rare disease that affects one in 3,500 to 10,000 children that delays or restricts growth caused by genetic mutations or as a disease acquired after birth.

We Believe NGENLA™ is Positioned to Gain Significant U.S. and Worldwide Share

Better Adherence

Market to consolidate from 7 daily treatments to 3 long-acting therapies

Growing Global Market

Estimated $5.5 billion market expected to expand by up to 12.3% annually due to better adherence to weekly treatment3

Next-Gen Innovation for Children

NGENLA™ approved in 40 markets worldwide for one in 3,500-10,0001,2 pediatric patients affected by GHD

Proudly Partnered with Pfizer

Pfizer pursuing additional approvals for other indications

1. National Organization for Rare Disorders. Growth Hormone Deficiency. 

2. Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):47-52. doi:10.1097/MED.0b13e32834ec952.

3. “Human Growth Hormone Market Size,” Grand View Research, Grand View Research, https://www.grandviewresearch.com/industry-analysis/human-growth-hormone-drugs-market

Expanding NGENLA's™ Potential

Adult growth hormone deficiency (AGHD) afflicts approximately 50,000 people in the U.S. There are two main causes: damage or trauma to the pituitary or hypothalamus gland, and being born with a growth hormone deficiency (GHD). Whereas growth hormone (GH) is principally used to assist growth in children, GH is necessary for GHD patients to maintain muscle, bone and fat tissues in a healthy balance and quality of life. Through our partnership with Pfizer, NGENLA’s potential to treat adult patients and related pediatric conditions is also under exploration.

See our pipeline
1 in 10K

<p>Adults diagnosed with GHD<sup>1</sup></p>

~1 in 3.8K

<p>Children in the U.S. have growth failure due to GHD<sup>2</sup></p>

Source

   National Center for Biotechnology Information